RegenxbioRGNX
RGNX
About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Employees: 353
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
4% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 53
1.77% less ownership
Funds ownership: 84.96% [Q4 2024] → 83.18% (-1.77%) [Q1 2025]
7% less funds holding
Funds holding: 177 [Q4 2024] → 164 (-13) [Q1 2025]
8% less capital invested
Capital invested by funds: $325M [Q4 2024] → $298M (-$27.4M) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 44
31% less call options, than puts
Call options by funds: $566K | Put options by funds: $818K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
29%
upside
Avg. target
$33
256%
upside
High target
$52
461%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Chardan Capital Daniil Gataulin | 461%upside $52 | Buy Maintained | 9 Jun 2025 |
Goldman Sachs Paul Choi | 29%upside $12 | Neutral Maintained | 17 Apr 2025 |
HC Wainwright & Co. Yi Chen | 267%upside $34 | Buy Reiterated | 21 Mar 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 267%upside $34 | Buy Maintained | 17 Mar 2025 |
Financial journalist opinion
Based on 5 articles about RGNX published over the past 30 days
Positive
Seeking Alpha
1 week ago
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA decision represents a significant catalyst for RGNX shares, offering a compelling pre-approval investment opportunity.
Positive
Benzinga
1 week ago
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.
Neutral
PRNewsWire
1 week ago
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Biomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated ages One new participant aged 2 years at dosing had expression level at 118.6% compared to control Favorable safety profile continues with no serious adverse events or adverse events of special interest observed Webcast to be held at 8:00 a.m. today ROCKVILLE, Md.
Neutral
PRNewsWire
1 week ago
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.
Neutral
PRNewsWire
3 weeks ago
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie ROCKVILLE, Md. , May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx).
Neutral
PRNewsWire
1 month ago
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Neutral
Seeking Alpha
1 month ago
REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chief Medical Officer Mitch Chan - CFO Conference Call Participants Mani Foroohar - Leerink Partners Gena Wang - Barclays Judah Frommer - Morgan Stanley Annabel Samimy - Stifel Paul Choi - Goldman Sachs Sean McCutcheon - Raymond James Eduardo Martinez-Montes - H.C. Wainwright Operator Welcome, everyone to the First Quarter 2025 REGENXBIO Earnings Conference Call.
Neutral
PRNewsWire
1 month ago
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS II Partner Nippon Shinyaku to lead commercialization upon potential approval REGENXBIO to lead commercial manufacturing and supply chain ROCKVILLE, Md. , May 13, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
Negative
Zacks Investment Research
1 month ago
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago.
Neutral
PRNewsWire
1 month ago
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025 FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continues Conference call today at 4:30 p.m. ET ROCKVILLE, Md.
Charts implemented using Lightweight Charts™